Eytan Abraham PhD

Dr. Eytan Abraham heads up the newly formed Cell Therapy Research & Technology (R&T) group in Walkersville, MD. Dr. Abraham’s R&T group develops and tests enabling technologies and methods to facilitate large scale cell therapy manufacturing for clinical trials and commercial use. One major R&T initiative is the use of bioreactor platforms to produce large numbers of various cell types to meet cell therapy commercialization need; while maintaining high-cell quality and reducing costs.

Previously at Pluristem Therapeutics, Dr. Abraham was Head of Product Innovation. This group developed a pipeline of MSC therapies tailored for different clinical indication, by altering various aspects of the 3-D bioreactor culture environment.

Dr. Abraham holds a Ph.D. in developmental biology from the University of Maryland Biotechnology Institute and conducted his post-doctoral training on tissue engineering and cell therapy at the Harvard-MIT Biomedical Engineering Center (HST) and Harvard Medical School.